AbbVie: Colitis, Ulcerative trials

The registry lists 52 Colitis, Ulcerative studies with AbbVie as lead sponsor. 7 are open to participants now and 22 have results posted.

Phase 1 4Phase 2 7Phase 3 21Phase 4 1No phase 21(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingNCT07697456Phase 2
• Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative ColitisRecruitingNCT07136116
• A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruitingNCT07071519Phase 3
• An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)RecruitingNCT06838845
• Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative ColitisRecruitingNCT06764706
• Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in BelgiumRecruitingNCT06581042
• Expanded Access to UpadacitinibAvailableNCT04159597
• Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative ColitisTerminatedNCT05785715Phase 2Results posted
• Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative ColitisCompletedNCT05570006Phase 2Results posted
• A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior TherapyCompletedNCT03695185Phase 2Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03653026Phase 3Results posted
• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03398148Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT02819635Phase 2/3Results posted
• Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)CompletedNCT02750800Results posted
• Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative ColitisCompletedNCT02632175Phase 3Results posted
• A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical PracticeCompletedNCT02499263Results posted
• Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuoTerminatedNCT02092389Results posted
• Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02065622Phase 3Results posted
• Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02065557Phase 3Results posted
• Special Investigation in Patients With Ulcerative ColitisCompletedNCT01947816Results posted
• Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeCompletedNCT01768858Results posted
• A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice SettingCompletedNCT01550965Phase 3Results posted
• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative ColitisTerminatedNCT01004185Phase 3Results posted
• A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT00853099Phase 3Results posted
• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative ColitisCompletedNCT00713310Phase 3Results posted
• Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)CompletedNCT00577473Phase 3Results posted
• Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative ColitisCompletedNCT00573794Phase 3Results posted
• A Comparison of Once a Day Dose Compared to 2 Doses/DayCompletedNCT00505778Phase 3Results posted
• Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative ColitisCompletedNCT00073021Phase 3Results posted
• A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingCompletedNCT07421258
• A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabActive, not recruitingNCT06880744Phase 3
• Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's DiseaseCompletedNCT06459297
• A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel DiseaseCompletedNCT06346288Phase 4
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisActive, not recruitingNCT06257875Phase 2
• An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in JapanCompletedNCT05791526
• Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.Active, not recruitingNCT05782907Phase 3
• Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative ColitisActive, not recruitingNCT05496348
• An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World PracticeActive, not recruitingNCT05494606
• A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisWithdrawnNCT05316220Phase 3
• Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisCompletedNCT04862741Phase 1
• Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female VolunteersCompletedNCT04458805Phase 1
• A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT04254783Phase 1
• A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative ColitisActive, not recruitingNCT03398135Phase 3
• Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceCompletedNCT03223012
• A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT03006068Phase 3
• Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life ConditionsCompletedNCT02738125
• Impact of Adalimumab on Patient-reported Outcomes in Ulcerative ColitisCompletedNCT02506179
• A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell LymphomaWithdrawnNCT02087878
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)Active, not recruitingNCT01848561
• Fecal Biomarker Study for Patients With Ulcerative ColitisCompletedNCT00780507
• A Double Blind Study for the Treatment of Acute Ulcerative ColitisCompletedNCT00350415Phase 3
• A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.TerminatedNCT00254618Phase 1